ATE435202T1 - Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung - Google Patents

Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung

Info

Publication number: ATE435202T1
Authority: AT; Austria
Prior art keywords: lower alkyl; gen; day; optionally substituted; alkyl
Prior art date: 2002-01-11

Application number

AT03701048T

Other languages

English (en)

Inventor

Takahide Nishi

Takaichi Shimozato

Futoshi Nara

Shojiro Miyazaki

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-11

Filing date

2003-01-09

Publication date

2009-07-15

2003-01-09 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2009-07-15 Application granted granted Critical

2009-07-15 Publication of ATE435202T1 publication Critical patent/ATE435202T1/de

Links

150000001414 amino alcohols Chemical class 0.000 title abstract 3
150000003007 phosphonic acid derivatives Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 10
229910052760 oxygen Inorganic materials 0.000 abstract 4
229930105110 Cyclosporin A Natural products 0.000 abstract 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 2
108010036949 Cyclosporine Proteins 0.000 abstract 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 2
125000002947 alkylene group Chemical group 0.000 abstract 2
239000003146 anticoagulant agent Substances 0.000 abstract 2
229960001265 ciclosporin Drugs 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
150000002688 maleic acid derivatives Chemical class 0.000 abstract 2
125000006239 protecting group Chemical group 0.000 abstract 2
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
230000002744 anti-aggregatory effect Effects 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
125000000732 arylene group Chemical group 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
-1 ethylene, vinylene, ethynylene Chemical group 0.000 abstract 1
208000024908 graft versus host disease Diseases 0.000 abstract 1
125000001188 haloalkyl group Chemical group 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
230000002537 thrombolytic effect Effects 0.000 abstract 1
239000012873 virucide Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)

AT03701048T 2002-01-11 2003-01-09 Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung ATE435202T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002004456		2002-01-11
JP2002004484		2002-01-11
PCT/JP2003/000136 WO2003059880A1 (en)	2002-01-11	2003-01-09	Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these

Publications (1)

Publication Number	Publication Date
ATE435202T1 true ATE435202T1 (de)	2009-07-15

Family

ID=26625490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03701048T ATE435202T1 (de)	2002-01-11	2003-01-09	Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung

Country Status (25)

Country	Link
US (5)	US7199150B2 (de)
EP (1)	EP1471054B1 (de)
JP (1)	JP4270541B2 (de)
KR (2)	KR20080035702A (de)
CN (1)	CN100406437C (de)
AT (1)	ATE435202T1 (de)
AU (1)	AU2003202495B2 (de)
BR (1)	BR0306811A (de)
CA (1)	CA2473461C (de)
CO (1)	CO5640126A2 (de)
CY (1)	CY1109457T1 (de)
DE (1)	DE60328161D1 (de)
DK (1)	DK1471054T3 (de)
ES (1)	ES2327825T3 (de)
IL (1)	IL162874A0 (de)
MX (1)	MXPA04006709A (de)
NO (1)	NO329134B1 (de)
NZ (1)	NZ533994A (de)
PL (1)	PL211954B1 (de)
PT (1)	PT1471054E (de)
RU (1)	RU2330839C2 (de)
SI (1)	SI1471054T1 (de)
TW (1)	TWI283574B (de)
WO (1)	WO2003059880A1 (de)
ZA (1)	ZA200406333B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4771511B2 (ja) *	2003-07-08	2011-09-14	第一三共株式会社	アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
RU2330839C2 (ru) *	2002-01-11	2008-08-10	Санкио Компани, Лимитед	Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
US7241790B2 (en) *	2002-07-30	2007-07-10	University Of Virginia Patent Foundation	Compounds active in spinigosine 1-phosphate signaling
GB0302094D0 (en) *	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
TW200510300A (en) *	2003-07-11	2005-03-16	Sankyo Co	Amino alcohol compounds
JP2007515501A (ja) *	2003-09-19	2007-06-14	ダウグローバルテクノロジーズインコーポレイティド	多官能性モノマー及びそれからのポリアリーレン組成物
GB0324269D0 (en) *	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
WO2005041899A2 (en)	2003-11-03	2005-05-12	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
ES2232306B1 (es) *	2003-11-10	2006-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
TWI355934B (en) *	2004-02-24	2012-01-11	Sankyo Co	Pharmaceutical composition for treatment or prophy
ATE502630T1 (de)	2004-07-16	2011-04-15	Kyorin Seiyaku Kk	Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
TW200611687A (en) *	2004-07-29	2006-04-16	Sankyo Co	Pharmaceutical compositions used for immunosuppressant
JP4919374B2 (ja) *	2004-07-29	2012-04-18	第一三共株式会社	免疫抑制剤としての医薬組成物
AU2005292984B2 (en) *	2004-10-12	2011-01-20	Kyorin Pharmaceutical Co., Ltd.	Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
JP5024851B2 (ja) *	2004-10-28	2012-09-12	第一三共株式会社	光学活性４，４−二置換オキサゾリジン誘導体とその製造方法
WO2006046595A1 (ja) *	2004-10-28	2006-05-04	Sankyo Company, Limited	光学活性４，４－二置換オキサゾリジン誘導体とその製造方法
MX2007009848A (es)	2005-02-14	2008-03-10	Univ Virginia	Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
TWI418350B (zh) *	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途
RU2421214C2 (ru) *	2005-10-07	2011-06-20	Киорин Фармасьютикал Ко., Лтд.	Терапевтическое средство для лечения гепатита и способ лечения гепатита
MX2008009579A (es)	2006-01-27	2008-09-25	Univ Virginia	Metodo para el tratamiento de dolor neuropatico.
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007212193A1 (en)	2006-02-09	2007-08-16	University Of Virginia Patent Foundation	Bicyclic sphingosine 1-phosphate analogs
TW200815600A (en)	2006-08-04	2008-04-01	Daiichi Sankyo Co Ltd	An enzyme for phosphorizing a medicine
JP5140593B2 (ja) *	2006-08-08	2013-02-06	杏林製薬株式会社	アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
US8232319B2 (en) *	2006-08-08	2012-07-31	Kyorin Pharmaceutical Co., Ltd.	Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
AU2007323618A1 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Tetralin analogs having sphingosine 1-phosphate agonist activity
EP2099741A2 (de)	2006-11-21	2009-09-16	University Of Virginia Patent Foundation	Hydrindan-analoga mit sphingosin-1-phosphatrezeptoragonistenaktivität
WO2008064337A2 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
TW200906389A (en)	2007-05-25	2009-02-16	Daiichi Sankyo Co Ltd	Pharmaceutical composition comprising of therapeutic or prophylactic agents for hepatitis
TW200946105A (en)	2008-02-07	2009-11-16	Kyorin Seiyaku Kk	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
FR2963238B1 (fr) *	2010-07-29	2012-12-28	Fournier Lab Sa	Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires
US20130190278A1 (en) *	2010-07-29	2013-07-25	Laboratoires Fournier Sa	Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
KR20130133198A (ko)	2010-12-02	2013-12-06	다이이찌 산쿄 가부시키가이샤	피롤 유도체 및 그 제조 방법
HK1210969A1 (en)	2012-01-20	2016-05-13	奥克塞拉有限公司	Substituted heterocyclic compounds for disease treatment
KR20180093177A (ko)	2017-02-10	2018-08-21	(주)홍익바이오텍	죽염과 다공성 광물을 이용한 개껌 제조방법
EP3886854A4 (de)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1134687A (en)	1966-04-28	1968-11-27	Beecham Group Ltd	Acetylenic compounds
IL36730A0 (en)	1970-05-28	1971-06-23	Chemagro Corp	Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
DK150068C (da)	1978-06-02	1987-06-29	Pfizer	Analogifremgangsmaade til fremstilling af aminothiazoler
FR2460919A1 (fr)	1979-07-11	1981-01-30	Prod Synthese Ste Indle	Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US4363918A (en)	1979-09-11	1982-12-14	Janssen Pharmaceutica N.V.	Method of preparing 1-alkyl-3-carboxy-1H pyrrole-2-acetic acids
SE8107537L (sv)	1980-12-22	1982-06-23	Delalande Sa	Nya derivat av heterocykliska aminoalcoyler, deras framstellningssett och deras terapeutiska anvendning
JPS58105946A (ja)	1981-12-18	1983-06-24	Tanabe Seiyaku Co Ltd	アミノブタノ−ルエステル誘導体の製法
US4716155A (en)	1981-12-24	1987-12-29	E. R. Squibb & Sons, Inc.	Phosphorus containing compounds and hypotensive use thereof
IT1190793B (it)	1982-04-27	1988-02-24	Magis Farmaceutici	Composti attivi nel trattamento dell'ulcera e sintomi allergici della pelle
JPS5944345A (ja)	1982-09-06	1984-03-12	Toyo Jozo Co Ltd	光学活性β―アミノ酸の製造法
US4536601A (en)	1982-09-28	1985-08-20	Dainippon Pharmaceutical Co., Ltd.	Optically active N-substituted phenylalaninols and use thereof
JPS5988467A (ja)	1982-11-09	1984-05-22	Yoshitomi Pharmaceut Ind Ltd	フエノキシアミノプロパノ−ル誘導体
DK302185A (da)	1984-07-05	1986-01-06	Rolland Sa A	2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
JPS62123126A (ja)	1985-08-20	1987-06-04	Yoshitomi Pharmaceut Ind Ltd	細胞ｄｎａ合成抑制因子
US4634689A (en) *	1985-10-31	1987-01-06	Schering Corporation	Phosphinylalkanoyl imino acids
US4667038A (en)	1985-12-02	1987-05-19	Syntex (U.S.A.) Inc.	Tetrahydroisoquinoline derivatives
US4792568A (en)	1986-04-14	1988-12-20	Rorer Pharmaceutical Corporation	Aryl pyrroles as useful antiallergy compounds
JPS63126897A (ja)	1986-05-02	1988-05-30	Yoshitomi Pharmaceut Ind Ltd	免疫抑制因子
JPH0778052B2 (ja)	1986-11-28	1995-08-23	富士薬品工業株式会社	Ｄｌ−パントラクトンの光学分割法
JPH01104087A (ja)	1987-03-17	1989-04-21	Yoshitomi Pharmaceut Ind Ltd	免疫抑制物質の製造法
US5135947A (en)	1987-04-09	1992-08-04	Eli Lilly And Company	1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
GB8712694D0 (en)	1987-05-29	1987-07-01	Scras	Tetrahydrofurans etc
IL86740A (en)	1987-06-30	1992-11-15	Tanabe Seiyaku Co	Thiphene derivatives,their preparation and pharmaceutical compositions containing them
EP0300688A1 (de)	1987-07-21	1989-01-25	FISONS plc	Pyrrol-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammenstellungen, die sie enthalten
CA1334975C (en)	1987-11-13	1995-03-28	James H. Holms	Furan and pyrrole containing lipoxygenase inhibiting compounds
US5039706A (en) *	1987-11-30	1991-08-13	Du Pont Merck Pharmaceutical Company	Antiinflammatory PLA2 inhibitors
NZ227365A (en)	1987-12-18	1990-10-26	Glaxo Group Ltd	Aromatic amino ethers and pharmaceutical compositions
US4977171A (en)	1988-06-09	1990-12-11	Yashima Chemical Industrial Co., Ltd.	Oxa- or thia-zoline derivative
WO1990002727A1 (fr)	1988-09-14	1990-03-22	Yoshitomi Pharmaceutical Industries, Ltd.	Immunodepresseur
JPH02256612A (ja)	1988-12-22	1990-10-17	Tanabe Seiyaku Co Ltd	消化管機能調整剤
US5266599A (en)	1989-02-20	1993-11-30	Jouveinal S.A.	Use of (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine to increase gastric discharge in a subject
US5068247A (en)	1989-07-07	1991-11-26	Yoshitomi Pharmaceutical Industries, Ltd.	2-aminopentanoic acid compounds and their use as immunosuppressants
HU212415B (en)	1989-08-25	1996-06-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing new cyclic oxym derivatives and pharmaceutical compositions containing them as active components
US5234934A (en)	1989-08-25	1993-08-10	Egis Gyogyszergyar	Aminopropanol derivatives, process for their preparation and pharmaceutical compositions comprising the same
FR2655043B1 (fr)	1989-11-24	1992-02-07	Adir	Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5037853A (en)	1989-12-28	1991-08-06	Abbott Laboratories	Cyclopropyl derivative lipoxygenase inhibitors
GB9000644D0 (en)	1990-01-11	1990-03-14	Erba Carlo Spa	New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
JPH0714905B2 (ja)	1990-02-20	1995-02-22	吉富製薬株式会社	２―アミノペンタン酸化合物の新規な製造法
US5274113A (en)	1991-11-01	1993-12-28	Molecular Probes, Inc.	Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5723218A (en)	1990-04-16	1998-03-03	Molecular Probes, Inc.	Dipyrrometheneboron difluoride labeled flourescent microparticles
US5326692B1 (en)	1992-05-13	1996-04-30	Molecular Probes Inc	Fluorescent microparticles with controllable enhanced stokes shift
US5433896A (en)	1994-05-20	1995-07-18	Molecular Probes, Inc.	Dibenzopyrrometheneboron difluoride dyes
US5648270A (en)	1995-02-06	1997-07-15	Molecular Probes, Inc.	Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5501980A (en)	1994-05-20	1996-03-26	Molecular Probes, Inc.	Benzazolylcoumarin-based ion indicators
JP2747849B2 (ja)	1990-08-24	1998-05-06	大鵬薬品工業株式会社	２’―デオキシヌクレオシド類の選択的アシル化方法
US5260322A (en)	1990-10-08	1993-11-09	Merck & Co., Inc.	Angiotension II antagonists in the treatment of hyperuricemia
GB9027055D0 (en)	1990-12-13	1991-02-06	Sandoz Ltd	Organic compounds
DK0492497T3 (da)	1990-12-24	1997-01-06	Hoechst Ag	Fremgangsmåde til acylering af alkoholer med en immobiliseret pseudomonas-lipase
CA2071621C (en)	1991-06-19	1996-08-06	Ahihiko Hosoda	Aldehyde derivatives
JP2805006B2 (ja)	1991-08-29	1998-09-30	財団法人工業技術研究院	チオフェン系化合物及びその薬理的に許容できる塩類よりなる医薬
NL9101623A (nl)	1991-09-26	1993-04-16	Dsm Nv	Werkwijze voor de bereiding van een alcohol.
ES2143993T3 (es)	1991-12-11	2000-06-01	Yoshitomi Pharmaceutical	Farmaco para tratar una enfermedad autoinmune.
JP3155099B2 (ja)	1991-12-24	2001-04-09	ウェルファイド株式会社	２−アミノブタン酸化合物
JPH0667229A (ja)	1992-08-14	1994-03-11	Fuji Photo Film Co Ltd	非線形光学材料
ATE154800T1 (de)	1992-08-25	1997-07-15	Searle & Co	N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
EP0627406B1 (de) *	1992-10-21	1998-10-28	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1, 3- propandiolverbindung und immunosuppressium
US5288751A (en)	1992-11-06	1994-02-22	Abbott Laboratories	[(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
GB9304589D0 (en)	1993-03-05	1993-04-21	Erba Carlo Spa	Biologically active ureido derivatives useful as antimetastic agents
GB9306473D0 (en)	1993-03-29	1993-05-19	Bioglan Lab Ltd	Pharmaceutically useful compounds
US5641783A (en)	1993-11-12	1997-06-24	Cell Therapeutics, Inc.	Substituted amino alcohol compounds
US5837703A (en)	1993-03-31	1998-11-17	Cell Therapeutics, Inc.	Amino-alcohol substituted cyclic compounds
JPH06345728A (ja)	1993-06-11	1994-12-20	Nissan Chem Ind Ltd	Ｎ−置換アゾール誘導体の製造方法
US5717605A (en) *	1993-10-14	1998-02-10	Olympus Optical Co., Ltd.	Color classification apparatus
JP3352184B2 (ja)	1993-11-12	2002-12-03	株式会社アズウェル	ピペラジン不飽和脂肪酸誘導体
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5534980A (en) *	1994-05-31	1996-07-09	Mita Industrial Co., Ltd.	Electrophotographic image forming apparatus having a charge removing means
US5948820A (en)	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
JP3870419B2 (ja)	1994-08-22	2007-01-17	三菱ウェルファーマ株式会社	ベンゼン化合物およびその医薬としての用途
JPH09124564A (ja)	1995-11-06	1997-05-13	Nikko Rika Kk	光学活性体混合物ならびにその製造方法
ATE279185T1 (de)	1995-12-28	2004-10-15	Mitsubishi Pharma Corp	2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
US6686353B1 (en)	1996-05-20	2004-02-03	Teijin Intellectual Property Center Limited	Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
JPH11209277A (ja)	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
DE69734215T2 (de)	1996-07-22	2006-06-29	Novo Nordisk A/S	Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
US6077954A (en)	1996-08-01	2000-06-20	Isis Pharmaceuticals, Inc.	Substituted heterocyclic compounds
EP0946180A4 (de)	1996-10-07	2003-07-23	Smithkline Beecham Corp	Methoden zur stimulierung der knochenbildung
US5891892A (en)	1996-10-29	1999-04-06	Warner-Lambert Company	Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
US5732218A (en) *	1997-01-02	1998-03-24	Lucent Technologies Inc.	Management-data-gathering system for gathering on clients and servers data regarding interactions between the servers, the clients, and users of the clients during real use of a network of clients and servers
DE69840169D1 (de)	1997-02-27	2008-12-11	Novartis Ag	Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
CA2286315C (en) *	1997-04-04	2007-03-06	Yoshitomi Pharmaceutical Industries Ltd.	2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
WO1999001420A1 (en)	1997-07-03	1999-01-14	Taito Co., Ltd.	Process for the preparation of 2-aminomalonic acid derivatives and intermediates used in the process
JPH1081623A (ja)	1997-07-11	1998-03-31	Yoshitomi Pharmaceut Ind Ltd	自己免疫疾患治療剤
NZ502872A (en)	1997-08-28	2002-10-25	Novartis Ag	Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
ES2237850T3 (es)	1997-10-14	2005-08-01	Mitsubishi Pharma Corporation	Compuestos de piperazina y su uso medicinal.
DE19745904A1 (de) *	1997-10-17	1999-04-22	Hoechst Ag	Polymerstabilisierte Metallkolloid-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Katalysatoren für Brennstoffzellen
JPH11343300A (ja)	1998-03-13	1999-12-14	Tetsuro Fujita	新規ハプテン、それを認識する抗体およびそれらを用いた免疫学的測定法
DE19817459A1 (de)	1998-04-20	1999-10-21	Basf Ag	Neue heterozyklische substituierte Amide, Herstellung und Anwendung
JP4079505B2 (ja)	1998-04-28	2008-04-23	田辺三菱製薬株式会社	２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールの新規な製造法
CN1332726A (zh)	1998-11-02	2002-01-23	卫福有限公司	吡咯烷化合物及其药物用途
ATE288414T1 (de)	1998-11-11	2005-02-15	Novartis Pharma Gmbh	Herstellung von 2-amino-2(2-(4- alkylphenyl)äthyl)propan-1,3-diolen
AU2164300A (en)	1998-12-04	2000-06-26	N.V. Organon	Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
US6525069B1 (en)	1998-12-18	2003-02-25	Bristol-Myers Squibb Pharma Co.	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE302005T1 (de)	1998-12-18	2005-09-15	Bristol Myers Squibb Pharma Co	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
US6178821B1 (en) *	1999-01-25	2001-01-30	General Electric Company	Vibration sensing device
KR100659007B1 (ko)	1999-02-10	2007-02-28	미츠비시 웰파마 가부시키가이샤	아미드 화합물 및 그 의약으로서의 용도
CN1144779C (zh)	1999-03-11	2004-04-07	杭州中美华东制药有限公司	制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
JP4627356B2 (ja)	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
MXPA02001095A (es)	1999-07-30	2002-08-20	Vertex Pharma	Derivados de amina ciclicos y aciclicos.
US6451823B1 (en)	1999-09-23	2002-09-17	G.D. Searle & Co.	Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
DE19963174A1 (de) *	1999-12-27	2001-07-12	Gruenenthal Gmbh	Substituierte Pyrrol-Mannichbasen
EP1244657B1 (de)	1999-12-31	2004-12-29	Encysive Pharmaceuticals Inc.	Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren
US6803375B1 (en)	2000-01-06	2004-10-12	The Regents Of The University Of California	Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
SK13652002A3 (sk)	2000-03-31	2004-01-08	Pfizer Products Inc.	Deriváty piperazínu
US6964676B1 (en) *	2000-04-14	2005-11-15	Scimed Life Systems, Inc.	Stent securement system
KR20030017502A (ko)	2000-04-28	2003-03-03	에프. 호프만-라 로슈 아게	파라(설포닐)아릴 및 헤테로아릴
JP2004516237A (ja)	2000-06-21	2004-06-03	ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー	ケモカイン受容体活性調節剤としてのピペリジンアミド類
NZ533997A (en) *	2000-07-13	2005-11-25	Sankyo Co	Amino alcohol derivatives
JP2002053575A (ja)	2000-08-09	2002-02-19	Sankyo Co Ltd	アミノアルコ−ル類
AU8533101A (en) *	2000-08-31	2002-03-13	Merck & Co Inc	Phosphate derivatives as immunoregulatory agents
DE10049483A1 (de)	2000-09-29	2002-05-02	Gruenenthal Gmbh	Substituierte 1-Aminobutan-3-ol-Derivate
DE10048714A1 (de)	2000-09-30	2002-04-11	Gruenenthal Gmbh	5-Amino-1-penlen-3-ol-Derivate
CA2435739A1 (en)	2001-02-22	2002-09-06	Novartis Ag	Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
US7326801B2 (en) *	2001-03-26	2008-02-05	Novartis Ag	2-amino-propanol derivatives
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
CN1236831C (zh)	2001-05-21	2006-01-18	茵捷特数码浮质有限公司	用于经肺部途径递送蛋白质的组合物
GB0117921D0 (en)	2001-07-23	2001-09-12	Novartis Ag	Organic compounds
GB0119172D0 (en)	2001-08-06	2001-09-26	Melacure Therapeutics Ab	Phenyl pyrrole derivatives
AU2002332289B2 (en)	2001-09-27	2007-05-10	Kyorin Pharmaceutical Co., Ltd.	Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE463478T1 (de)	2001-09-27	2010-04-15	Kyorin Seiyaku Kk	Diaryletherderivat, dessen additionssalz und immunosuppressivum
GB0125443D0 (en)	2001-10-23	2001-12-12	Novartis Ag	Organic Compounds
US7361671B2 (en)	2001-11-15	2008-04-22	The Institute For Pharmaceutical Discovery, Inc.	Substituted heteroarylalkanoic acids
MXPA04005428A (es) *	2001-12-06	2004-12-06	Elan Pharm Inc	Hidroxietilaminas substituidas.
RU2330839C2 (ru) *	2002-01-11	2008-08-10	Санкио Компани, Лимитед	Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
JP4771511B2 (ja)	2003-07-08	2011-09-14	第一三共株式会社	アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
JP2003267974A (ja)	2002-01-11	2003-09-25	Sankyo Co Ltd	アミノアルコ−ル誘導体を含有する医薬組成物
US20040058894A1 (en)	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
CA2483594C (en)	2002-05-16	2011-02-15	Novartis Ag	Use of edg receptor binding agents in cancer
AU2003273865A1 (en)	2002-09-13	2004-04-30	Novartis Ag	Amino-propanol derivatives
MXPA05003254A (es)	2002-09-24	2005-06-08	Novartis Ag	Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
TWI355934B (en) *	2004-02-24	2012-01-11	Sankyo Co	Pharmaceutical composition for treatment or prophy
TW200611687A (en) *	2004-07-29	2006-04-16	Sankyo Co	Pharmaceutical compositions used for immunosuppressant
TWI418350B (zh)	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途

2003
- 2003-01-09 RU RU2004121143/04A patent/RU2330839C2/ru not_active IP Right Cessation
- 2003-01-09 AT AT03701048T patent/ATE435202T1/de active
- 2003-01-09 KR KR1020087006865A patent/KR20080035702A/ko not_active Withdrawn
- 2003-01-09 AU AU2003202495A patent/AU2003202495B2/en not_active Ceased
- 2003-01-09 PL PL370790A patent/PL211954B1/pl unknown
- 2003-01-09 ES ES03701048T patent/ES2327825T3/es not_active Expired - Lifetime
- 2003-01-09 BR BR0306811-0A patent/BR0306811A/pt not_active IP Right Cessation
- 2003-01-09 PT PT03701048T patent/PT1471054E/pt unknown
- 2003-01-09 CA CA2473461A patent/CA2473461C/en not_active Expired - Fee Related
- 2003-01-09 KR KR1020047010719A patent/KR100836547B1/ko not_active Expired - Fee Related
- 2003-01-09 IL IL16287403A patent/IL162874A0/xx not_active IP Right Cessation
- 2003-01-09 DE DE60328161T patent/DE60328161D1/de not_active Expired - Lifetime
- 2003-01-09 EP EP03701048A patent/EP1471054B1/de not_active Expired - Lifetime
- 2003-01-09 MX MXPA04006709A patent/MXPA04006709A/es active IP Right Grant
- 2003-01-09 CN CNB038059258A patent/CN100406437C/zh not_active Expired - Fee Related
- 2003-01-09 WO PCT/JP2003/000136 patent/WO2003059880A1/ja not_active Ceased
- 2003-01-09 DK DK03701048T patent/DK1471054T3/da active
- 2003-01-09 NZ NZ533994A patent/NZ533994A/xx not_active IP Right Cessation
- 2003-01-09 SI SI200331668T patent/SI1471054T1/sl unknown
- 2003-01-10 JP JP2003004599A patent/JP4270541B2/ja not_active Expired - Fee Related
- 2003-01-10 TW TW092100460A patent/TWI283574B/zh not_active IP Right Cessation
2004
- 2004-07-12 US US10/889,657 patent/US7199150B2/en not_active Expired - Fee Related
- 2004-07-12 CO CO04065919A patent/CO5640126A2/es active IP Right Grant
- 2004-08-10 ZA ZA2004/06333A patent/ZA200406333B/en unknown
- 2004-08-10 NO NO20043319A patent/NO329134B1/no not_active IP Right Cessation
2006
- 2006-12-11 US US11/636,776 patent/US20070105933A1/en not_active Abandoned
2007
- 2007-01-09 US US11/651,205 patent/US7638551B2/en not_active Expired - Fee Related
2009
- 2009-07-24 US US12/460,884 patent/US8067396B2/en not_active Expired - Fee Related
- 2009-08-12 US US12/583,001 patent/US8101650B2/en not_active Expired - Fee Related
- 2009-09-30 CY CY20091101015T patent/CY1109457T1/el unknown

Also Published As

Publication number	Publication date
US8067396B2 (en)	2011-11-29
JP2003267950A (ja)	2003-09-25
AU2003202495A1 (en)	2003-07-30
KR100836547B1 (ko)	2008-06-10
US20070142335A1 (en)	2007-06-21
JP4270541B2 (ja)	2009-06-03
BR0306811A (pt)	2004-10-26
US20100035842A1 (en)	2010-02-11
CN100406437C (zh)	2008-07-30
KR20080035702A (ko)	2008-04-23
PL370790A1 (en)	2005-05-30
RU2330839C2 (ru)	2008-08-10
WO2003059880A1 (en)	2003-07-24
NO329134B1 (no)	2010-08-30
US7199150B2 (en)	2007-04-03
EP1471054B1 (de)	2009-07-01
CA2473461A1 (en)	2003-07-24
US20070105933A1 (en)	2007-05-10
CA2473461C (en)	2011-11-01
AU2003202495B2 (en)	2006-07-20
PT1471054E (pt)	2009-09-23
NO20043319L (no)	2004-10-05
NZ533994A (en)	2006-10-27
US20090326038A1 (en)	2009-12-31
DE60328161D1 (de)	2009-08-13
ZA200406333B (en)	2005-12-28
RU2004121143A (ru)	2006-02-27
HK1066532A1 (en)	2005-03-24
MXPA04006709A (es)	2004-10-04
CO5640126A2 (es)	2006-05-31
ES2327825T3 (es)	2009-11-04
KR20040075068A (ko)	2004-08-26
CN1630635A (zh)	2005-06-22
EP1471054A1 (de)	2004-10-27
TW200302087A (en)	2003-08-01
IL162874A0 (en)	2005-11-20
US8101650B2 (en)	2012-01-24
PL211954B1 (pl)	2012-07-31
SI1471054T1 (sl)	2009-12-31
CY1109457T1 (el)	2014-08-13
EP1471054A4 (de)	2005-06-08
TWI283574B (en)	2007-07-11
US7638551B2 (en)	2009-12-29
DK1471054T3 (da)	2009-11-09
US20050043386A1 (en)	2005-02-24

Legal Events

Date

Code

Title

Description

2010-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1471054

Country of ref document: EP

2011-01-15

UEP